FDA Approves Embryonic Stem Cell-Based Therapy For Patients With Acute Spinal Cord Injury

The US FDA (Food and Drug Administration) has lifted a clinical hold on Geron’s Investigational New Drug (IND) application – the Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may now go ahead. GRNOPC1 is the first ever clinical trial of a human embryonic stem cell based therapy in humans…

[Read the full article here]

Comments are closed.